Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 9/20 | 0.55 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208211 | 0.96 | NR1H4 (0.55) | NR1H4MAOBPARP15PARP10ABCB1 | |
| SCHEMBL2087923 | 0.94 | NR1H4 (0.62) | NR1H4MAOBPARP15PARP10PARP2 | |
| SCHEMBL16787927 | 0.87 | SLC6A2 (0.55) | NR1H4MAOBMAOATDP1 | |
| SCHEMBL31661845 | 0.87 | NR1H4 (0.68) | NR1H4PARP15PARP10PARP2KAT6A | |
| SCHEMBL3069471 | 0.87 | NR1H4 (0.68) | NR1H4PARP15PARP10PARP2KAT6A | |
| SCHEMBL20239535 | 0.84 | MAOB (0.54) | NR1H4MAOBMAOAABCB1NPC1 | |
| SCHEMBL30575478 | 0.84 | NR1H4 (0.68) | NR1H4PARP15PARP10PARP2KAT6A | |
| SCHEMBL931299 | 0.84 | NR1H4 (0.68) | NR1H4PARP15PARP10PARP2KAT6A | |
| SCHEMBL20897525 | 0.83 | NR1H4 (0.54) | NR1H4PARP15PARP10KAT6A | |
| SCHEMBL23717221 | 0.82 | NR1H4 (0.47) | NR1H4PARP15PARP10KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-8604083-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-24 | — | — | US | disclosed |
| US-8552062-B2 | Methods for the treatment of metabolic disorders such as diabetes | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8487000-B2 | 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | Wellstat Therapertics Corporation (US) | 2013-07-16 | — | — | US | disclosed |
| US-7863475-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7851494-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7547802-B2 | 5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pent-4-enoic acid ethyl ester; insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, arteriosclerosis; side effects reduction; orally active | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-06-16 | — | — | US | disclosed |
| US-7329782-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20040267025-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040236100-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-05-20 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267025-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885PARP15 3746/4885 |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885PARP15 3746/4885 |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885PARP15 3746/4885 |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885PARP15 3746/4885 |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885PARP15 3746/4885 |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885PARP15 3746/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885PARP15 3746/4885 |
| US-20040236100-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885PARP15 3746/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885PARP15 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.